Teva Pharmaceutical Industries (TEVA) Stock Rating Upgraded by ValuEngine
Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Tuesday.
Several other brokerages have also commented on TEVA. Cantor Fitzgerald set a $10.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Monday, November 27th. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Goldman Sachs Group restated a “neutral” rating and set a $21.00 target price (down previously from $28.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 31st. BTIG Research upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Monday, September 11th. Finally, Morgan Stanley set a $15.00 target price on Teva Pharmaceutical Industries and gave the company an “underweight” rating in a research report on Thursday, October 5th. Seven equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $21.65.
Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.01 during mid-day trading on Tuesday, hitting $15.06. The stock had a trading volume of 10,220,158 shares, compared to its average volume of 15,647,037. The firm has a market capitalization of $15,500.00, a PE ratio of 3.52 and a beta of 0.55. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $38.31.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.